Skip to content

Depression: all studies

Page 598 of 1,034: studies 5,971 to 5,980 of 10,336, newest first. Back to the depression overview

Research

Structural neural plasticity evoked by rapid-acting antidepressant interventions.

Nature Reviews Neuroscience February 1, 2025 Clara Liao, Alisha N Dua, Cassandra Wojtasiewicz et al. 60 citations

A feature in the pathophysiology of major depressive disorder (MDD), a mood disorder, is the impairment of excitatory synapses in the prefrontal cortex. Intriguingly, different types of treatment with fairly rapid antidepressant effects (within days or a few weeks), such as ketamine, electroconvulsive therapy and non-invasive neurostimulation, seem to converge on enhancement of neural...

5-HT1B receptor activation produces rapid antidepressant-like effects in rodents.

Pharmacology, Biochemistry, and Behavior February 1, 2025 Erin A Clark, Lien Wang, Taleen Hanania et al. 5 citations

Ketamine is noted for its rapid onset antidepressant response and effectiveness in patients with treatment resistant depression. While most research has focused on glutamatergic mechanisms, recent studies show that antidepressant-like effects in rodents are dependent upon the serotonergic (5-HT) system and suggest a potential contribution of the 5-HT1B receptor. In this study we utilized...

DOI: 10.1016/j.pbb.2024.173917 (opens in new tab) Full text (opens in new tab) Synaptic plasticity 5-ht1b receptor agonist Lateral habenula circuit Rapid onset +5

Efficacy of esketamine nasal spray over quetiapine extended release over the short and long term: sensitivity analyses of ESCAPE-TRD, a randomised phase IIIb clinical trial.

The British Journal of Psychiatry February 1, 2025 Allan H. Young, Pierre-Michel Llorca, Andrea Fagiolini et al. 7 citations

In patients with treatment resistant depression (TRD), the ESCAPE-TRD study showed esketamine nasal spray was superior to quetiapine extended release. To determine the robustness of the ESCAPE-TRD results and confirm the superiority of esketamine nasal spray over quetiapine extended release. ESCAPE-TRD was a randomised, open-label, rater-blinded, active-controlled phase IIIb trial. Patients had...

DOI: 10.1192/bjp.2024.124 (opens in new tab) Full text (opens in new tab) Esketamine nasal spray Long-term treatment Quetiapine extended release Sensitivity analysis +6

Lutein Exerts Antioxidant and Neuroprotective Role on Schizophrenia-Like Behaviours in Mice.

International Journal of Developmental Neuroscience February 1, 2025 Helia Aziziha, Shahin Hassanpour, Morteza Zendehdel 2 citations

Schizophrenia is an esteemed neuropsychiatric condition delineated by the manifestation which role of the N-methyl-D-aspartate receptor (NMDAR) is important. Lutein administration exhibits protective effects via NMDA receptors. Thus, the main goal of this research was to investigate how lutein can possibly act as an antioxidant and provide protection for the brain against schizophrenia-like...

Examining differences in the effects and contexts of naturalistic psilocybin use for White participants vs. Participants of Color: A longitudinal online survey study.

Journal of Affective Disorders February 1, 2025 Grant Jones, Matthew X. Lowe, Sandeep M. Nayak et al. 12 citations

Psilocybin (a psychoactive compound found in "magic mushrooms" or "shrooms") has been gaining increased attention in research and popular culture as a number of clinical and observational studies have demonstrated that it may have potential for improving mental wellbeing. Relatedly, there has been a substantial uptick in naturalistic (e.g., real-world, non-clinical) psilocybin use in the United...

DOI: 10.1016/j.jad.2024.10.058 (opens in new tab) Full text (opens in new tab) Psilocybin Psychedelic medicine Hallucinogenic treatment Racial inequities +7

Application of microarray patches for the transdermal administration of psychedelic drugs in micro-doses.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V February 1, 2025 Octavio E Fandiño, Aaron R J Hutton, Chunyang Zhang et al. 4 citations

Throughout history, psychedelic compounds have been used for religious, spiritual and recreational purposes. A plethora of studies have reported the use of psychedelic compounds in the treatment of various conditions, such as alcoholism, addictions, depressive state to borderline schizophrenia, personality disorder, among other mental disorders. Psychedelic microdosing, a common technique in...

The Acceptability of Psychedelic‐Assisted Therapy Amongst Mental Health Consumers: Utilising the Theory of Planned Behaviour

International Journal of Mental Health Nursing February 1, 2025 Eva Louie, Ellen Towers, Alyssa R Morse et al. 2 citations

ABSTRACT Australian government approval has been granted for 3,4‐methylenedioxy‐methamphetamine (MDMA) treatment of post‐traumatic stress disorder and psilocybin for treatment‐resistant depression, but the process of translating psychedelic‐assisted therapies (PAT) into more widespread use is complex. Along with establishing the efficacy and feasibility of PATs, their acceptability amongst...

DOI: 10.1111/inm.70010 (opens in new tab) Psychedelic therapy Acceptability Mental health consumer Psychedelic‐assisted therapy +4

Psychedelics in neuroinflammation: Mechanisms and therapeutic potential

Progress in Neuro-Psychopharmacology and Biological Psychiatry January 31, 2025 Júnia L. de Deus, Juliana Marino Maia, Renato Nery Soriano et al. 27 citations

Neuroinflammation is a critical factor in the pathogenesis of various neurodegenerative and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and major depressive disorder. Psychedelics, such as psilocybin, lysergic acid diethylamide (LSD), and dimethyltryptamine (DMT), have demonstrated promising therapeutic effects on neuroinflammation, primarily through interactions...

A scoping review on randomized controlled trials investigating effects of breathwork in women with breast cancer

Research Square January 30, 2025 Vinitha Ganesan, Kathryn Kaiser, Anjani Allada et al. preprint

Abstract Background: Patients with breast cancer experience distress, treatment-related discomfort, and fear of recurrence, from initial diagnosis through survivorship. Aims: This study aimed to assess the effects of breathwork interventions on the mental health and quality of life of breast cancer patients and survivors. Methods: We searched multiple databases for randomized controlled trials...

Centering prayer in the treatment of Post-Traumatic Stress Disorder (PTSD)

World Journal of Advanced Research and Reviews January 30, 2025 Yanín Machado, Mauricio Chinchilla, Calixto Machado et al.

Post-traumatic stress disorder (PTSD) is a mental and behavioral disorder that develops from experiencing a traumatic event. A significant proportion of sexual assault survivors develop PTSD. Research indicates that 75% of sexual assault survivors meet the criteria for PTSD one month after the assault. PTSD treatment combines psychotherapy, medication, hypnosis, meditation, and emerging...